Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Eliciting the Discount Parameter in a Power Prior Method on the Basis of the Type I Error Consideration

A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Power Priors Based on Multiple Historical Studies for Binary Outcomes

Elastic Meta-Analytic-predictive Prior for Dynamically Borrowing Information from Historical Data with Application to Biosimilar Clinical Trials.

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials

Incorporating Historical Information to Improve Phase I Clinical Trials

Including historical data in the analysis of clinical trials: Is it worth the effort?

Sample size calculation for clinical trials analyzed with the meta‐analytic‐predictive approach

Bayesian design using adult data to augment pediatric trials

Bayesian Optimal Phase II Design for Randomized Clinical Trials

Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure

A review of Bayesian perspectives on sample size derivation for confirmatory trials

Conditional Power and Friends: The Why and How of (Un)planned, Unblinded Sample Size Recalculations in Confirmatory Trials

Bayesian design of clinical trials using the scale transformed power prior

A Bayesian Basket Trial Design Using Local Power Prior

Simplification or simulation: Power calculation in clinical trials

Estimating the Sampling Distribution of Posterior Decision Summaries in Bayesian Clinical Trials

A Bayesian approach on sample size calculation for comparing means.

Bayesian hybrid dose-finding design in phase I oncology clinical trials.